Related Experiment Video

Updated: Jul 7, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.1K

Superfamily II helicases: the potential therapeutic target for cardiovascular diseases

Tianxiang Fang1,2,3,4, Xizhi Wang5, Ning Huangfu2,3,4

  • 1Health Science Center, Ningbo University, Ningbo, China.

Frontiers in Cardiovascular Medicine
|December 28, 2023
PubMed

Insights

Superfamily II (SFII) helicases are crucial enzymes involved in nucleic acid metabolism. This review explores their role in cardiovascular diseases (CVDs), identifying potential therapeutic targets for conditions like atherosclerosis and heart failure.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cardiology
  • Genetics

Background:

  • Cardiovascular diseases (CVDs) remain a leading cause of global mortality.
  • Helicases, enzymes vital for nucleic acid metabolism, influence gene expression, inflammation, and lipid metabolism.
  • Aberrant helicase activity is linked to various human diseases, including cancer and immune disorders.

Purpose of the Study:

  • To comprehensively review the regulatory mechanisms of Superfamily II (SFII) helicases in the pathogenesis of CVDs.
  • To highlight the involvement of SFII helicases in specific cardiovascular conditions such as atherosclerosis, myocardial infarction, cardiomyopathies, and heart failure.
  • To identify SFII helicases as potential therapeutic targets for CVDs.

Main Methods:

  • Literature review focusing on the role of SFII helicases in cardiovascular disease.
  • Analysis of studies investigating the molecular mechanisms of SFII helicase regulation in CVDs.
  • Synthesis of current evidence linking SFII helicase function to cardiovascular pathology.

Main Results:

  • SFII helicases play a significant role in the molecular pathways underlying various CVDs.
  • Dysregulation of specific SFII helicases is associated with the development and progression of atherosclerosis, myocardial infarction, cardiomyopathies, and heart failure.
  • Understanding SFII helicase function provides insights into novel therapeutic strategies for CVDs.

Conclusions:

  • SFII helicases are critical players in cardiovascular health and disease.
  • Targeting SFII helicase pathways offers a promising avenue for novel CVD treatments.
  • Further research into SFII helicase mechanisms can lead to improved patient outcomes for cardiovascular conditions.

Keywords:
Brg1DEAD-boxRIG-I-likecardiovascular diseasestherapeutic target

More Related Videos

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

1.8K
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.4K

Related Concept Videos

DNA Helicases00:55

DNA Helicases

DNA unwinding helicase enzymes are a type of motor protein. Motor proteins can translocate along filaments or polymers using energy generated from ATP hydrolysis. Helicases are involved in all the important cellular processes where DNA unwinding is required, such as DNA replication, repair, recombination, and transcription. They are present in all living organisms, but vary in their structure, function, and mechanism of action. For example, in prokaryotes, DnaB helicase binds and translocates...
21.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
13.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
746
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433